| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Outline of Final Research Achievements |
We reported that SFα9, α9 integrin splicing variant, is a functional modulator of wild-type α9 integrin. We identified a inhibitor, which inhibits α9 integrin function, by exploring SFα9-binding molecules. The inhibitor protects mice from various autoimmune diseases.
We identified α4 integrin splicing variant, α4B. Although cells expressing α4B only have little binding to ligands of wild-type, cells co-expressing wild-type α4 integrin and α4B exhibits inhibition of wild-type α4 integrin-dependent cell adhesion. Thus, α4B is a endogenous inhibitory molecule for wild-type α4 integrin.
|
